SCHEDULE: Fresenius Medical Care's Humacyte Stake Dips to 9.9%
Beneficial Ownership Update
Fresenius Medical Care AG's beneficial ownership in Humacyte, Inc. decreased to 9.9% due to share dilution, while announcing a new CEO for its Care Enablement segment.
Summary
- Fresenius Medical Care AG (FME AG) and its subsidiary Fresenius Medical Care Holdings, Inc. (FMCH) filed Amendment No. 5 to their Schedule 13D regarding Humacyte, Inc.
- FMCH beneficially owns 18,312,735 shares of Humacyte's Common Stock.
- This represents approximately 9.9% of Humacyte's outstanding voting shares, calculated based on 184,778,911 shares outstanding as of October 8, 2025.
- The percentage decreased from 11.8% (reported in Amendment No. 4) solely due to an increase in Humacyte's total outstanding shares following a recent offering, not from any sale by Fresenius.
- FME AG announced the appointment of Joseph E. (Joe) Turk as a member of its Management Board, effective January 1, 2026, to serve as Chief Executive Officer of its Care Enablement segment, succeeding Dr. Katarzyna Mazur-Hofsaess.
Sentiment
Score: 5
Explanation: The filing is largely informational, detailing a change in percentage ownership due to dilution and an internal management change at the reporting entity. No significant positive or negative operational news for Humacyte.
Positives
- Fresenius Medical Care AG and FMCH have not disposed of any Humacyte shares since their initial filing in September 2021, indicating a continued long-term holding strategy.
- Fresenius Medical Care AG announced a new CEO for its Care Enablement segment, Joseph E. (Joe) Turk, effective January 1, 2026, which could signal strategic leadership focus within the parent company.
Negatives
- Fresenius Medical Care AG's beneficial ownership percentage in Humacyte, Inc. decreased from 11.8% to 9.9%, reducing its relative influence.
Risks
- The reporting person's percentage of beneficial ownership in Humacyte, Inc. is subject to dilution from future issuances of Humacyte's common stock.
Future Outlook
The filing does not provide specific forward-looking statements or guidance regarding Humacyte, Inc.'s future performance or Fresenius Medical Care AG's investment strategy beyond its continued beneficial ownership.
Management Comments
- Fresenius Medical Care AG announced the appointment of Joseph E. (Joe) Turk as a member of its Management Board, effective January 1, 2026, to lead the Care Enablement segment.
Industry Context
This Schedule 13D amendment reflects a routine update to beneficial ownership following a public offering by Humacyte, Inc., which diluted existing shareholders' percentage stakes. The internal management change at Fresenius Medical Care AG is part of its ongoing corporate governance and strategic adjustments within its Care Enablement segment, a common practice for large multinational healthcare companies.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Member of the Management Board, Chief Executive Officer of the Care Enablement segment (for Fresenius Medical Care AG) | Dr. Katarzyna Mazur-Hofsaess | Joseph E. (Joe) Turk | January 1, 2026 | Succession |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Management Board Appointment | Joseph E. (Joe) Turk appointed as a member of the Management Board of Fresenius Medical Care AG, succeeding Dr. Katarzyna Mazur-Hofsaess as CEO of the Care Enablement segment. | January 1, 2026 | This change is internal to the reporting entity (Fresenius Medical Care AG) and is expected to impact the strategic direction and operations of its Care Enablement segment. |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders (Humacyte): Existing shareholders experienced dilution due to the offering, reducing the percentage ownership of large holders like Fresenius.
- Shareholders (Fresenius Medical Care AG): The filing confirms continued holding of Humacyte shares, indicating ongoing strategic interest. The internal management change aims to strengthen leadership in a key segment.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| September 2, 2021 | Original Schedule 13D filed by Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG. |
| December 1, 2023 | Amendment No. 1 to Schedule 13D filed. |
| March 7, 2024 | Amendment No. 2 to Schedule 13D filed. |
| November 18, 2024 | Amendment No. 3 to Schedule 13D filed. |
| May 22, 2025 | Amendment No. 4 to Schedule 13D filed. |
| October 1, 2025 | Fresenius Medical Care AG announced the appointment of Joseph E. (Joe) Turk to its Management Board. |
| October 6, 2025 | Date of Humacyte, Inc.'s Prospectus Supplement for an offering. |
| October 8, 2025 | Date of event requiring the filing of this statement, reflecting the number of Humacyte shares outstanding after the offering. |
| October 16, 2025 | Date of signing this Amendment No. 5 to Schedule 13D. |
| January 1, 2026 | Effective date of Joseph E. (Joe) Turk's appointment as CEO of the Care Enablement segment for Fresenius Medical Care AG. |
Recommendation
holdThe filing indicates that Fresenius Medical Care AG and its subsidiary continue to hold a significant stake in Humacyte, Inc., despite the percentage ownership decreasing due to dilution from Humacyte's recent offering. There is no indication of a change in investment strategy or disposition of shares by Fresenius. The internal management change at Fresenius is not directly related to Humacyte's operational performance. Therefore, a 'hold' recommendation is appropriate as the core investment thesis remains unchanged based on this filing.
Keywords
Humacyte, Fresenius Medical Care, Schedule 13D, beneficial ownership, shareholding, dilution, management change, Care Enablement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.